This is the authors' abstract. We don't add key points for this paper.
[ 11 C]TGN-020 has been developed as a positron emission tomography (PET) tracer for imaging aquaporin-4 (AQP4) in the brain and used in clinical studies. Previously, [ 11 C]TGN-020 was synthesized through the acylation of [ 11 C]nicotinic acid, produced by the reaction of 3-bromopyridine and n -butyllithium with [ 11 C]CO 2 , with 2-amino-1,3,4-thiadiazole. In this study, to enhance the automated radiosynthesis efficiency of [ 11 C]TGN-020, we optimized its radiosynthesis procedure using our in-house developed 11 C-labeling synthesizer. [ 11 C]TGN-020 was synthesized via direct [ 11 C]CO 2 fixation using n -butyllithium and 3-bromopyridine in tetrahydrofuran, followed by treatment of lithium [ 11 C]nicotinic acetate with isobutyl chloroformate and subsequent acylation with 2-amino-1,3,4-thiadiazole in the presence of N , N -diisopropylethylamine. The optimized process significantly improved the radiosynthesis efficiency of [ 11 C]TGN-020, achieving a high radiochemical yield based on [ 11 C]CO 2 (610‒1700 MBq, 2.8 ± 0.7%) at the end of synthesis ( n = 12) and molar activity ( A m ) of 160–360 GBq/μmol at the end of synthesis ( n = 5). The radiosynthesis time and radiochemical purity were approximately 60 min and > 95% ( n = 12), respectively. PET studies based on [ 11 C]TGN-020 with different A m values were performed using healthy rats. The radioactive uptake of [ 11 C]TGN-020 with high A m in the cerebral cortex was slightly higher than that with low A m . [ 11 C]TGN-020 with high A m was obtained in reproducible radiochemical yield. Overall, the proposed optimization process for the radiosynthesis of [ 11 C]TGN-020 can facilitate its application as a PET radiopharmaceutical for clinical use.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kawamura et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: